An investigational gamma-secretase modulator designed for the treatment of Alzheimer’s disease led to an efficient and long-lasting reduction of toxic amyloid-beta 42 peptide in cell cultures and mouse brain cells, according to data from a recent study. In mice, the compound, called AC-0027875, was also able to penetrate the brain in high concentrations, which is an important feature of effective therapies for Alzheimer’s, according to the compound’s developer, AlzeCure Pharma. “AC-0027875 has a promising profile…
May 11, 2022May 11, 2022